Drugs / BZL101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00454532 | Mar 2007 → Dec 2009 | breast cancer | Bionovo | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00907959 | Jan 2012 → Jan 2015 | breast cancer | Bionovo | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BZL101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00454532 ↗ |
| Known as | Scutellaria barbata | “A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer.” PMID 20054647 ↗ Feb 2010 |
| Route | Oral | “oral administration of BZL101 was safe, well tolerated, and showed promising clinical evidence of anticancer activity” PMID 20054647 ↗ Feb 2010 |